• Home
  • ÀÚ·á½Ç
  • ÀϹÝÀÎÀ» À§ÇÑ ÀÚ·á½Ç

ÀϹÝÀÎÀ» À§ÇÑ ÀÚ·á½Ç

Á¦¸ñ ´ç´¢º´¼º Á·ºÎ ±Ë¾ç ȯÀÚ¿¡¼­ÀÇ µ¿¸ÆÀç°³Åë¼ú
´ç´¢º´¼º Á·ºÎ ±Ë¾ç ȯÀÚ¿¡¼­ÀÇ µ¿¸ÆÀç°³Åë¼ú



°æºÏ´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ¿Ü°úÇб³½Ç Çã ½Â



¼­ ·Ð



ÇöÀç ±¹³»¿¡¼­µµ ¼­±¸¿Í ¸¶Âù°¡Áö·Î ´ç´¢º´ ȯÀÚÀÇ À¯º´·üÀÌ ²ÙÁØÈ÷ Áõ°¡ÇÏ°í ÀÖ´Ù. 2Çü ´ç´¢º´ÀÇ °æ¿ì 30³â Àü°ú ºñ±³Çϸé 5¹è Á¤µµÀÇ Áõ°¡¸¦ º¸À̸ç, 2010³â¿¡´Â 3,500,000¸íÀÇ È¯ÀÚ°¡ 2Çü ´ç´¢º´À» ¾Î°í ÀÖ´Â °ÍÀ¸·Î º¸°íµÇ°í ÀÖ´Ù(1,2). ´ç´¢º´ÀÇ ÀÇÇÑ ´ç´¢Á·ÀÇ ¹ß»ý, Á·ºÎ °¨¿°Áõ, Á·ºÎ ±Ë¾ç µîÀÇ ¿¹¹æ°ú Ä¡·á¿¡ ´ëÇÑ Áöħ¼­µéÀÌ ±¹³»¿Ü¿¡¼­ °³¹ßµÇ¾î ³Î¸® »ç¿ëµÇ°í ÀÖÀ¸³ª(3-6), ´ç´¢º´¿¡ º´¹ßµÈ ±Þ¹ÚÇÏÁöÇãÇ÷ÁõÀº ¿©ÀüÈ÷ ÇÏÁöÀý´Ü ¹× »ç¸ÁÀÇ ÁÖ¿äÇÑ À§ÇèÀÎÀÚ·Î ¿©°ÜÁö°í ÀÖ´Ù(7). ´ç´¢º´¿¡ º´¹ßµÈ ¸»Ãʵ¿¸ÆÆó»öÁõÀº ´ç´¢º´ÀÌ ¾ø´Â °æ¿ì¿Í »ç¹µ ´Ù¸¥ ÀÓ»ó ¾ç»óÀ» º¸ÀÌ°í ÀÖÀ¸¸ç, ƯÈ÷ Á·ºÎ ±Ë¾çÀÌ ¹ß»ýÇÑ °æ¿ì¿¡´Â º¸´Ù º¹ÀâÇÏ°í Áï°¢ÀûÀÎ Ä¡·á¸¦ ¿äÇÏ´Â °æ¿ì°¡ ¸¹´Ù. ¾ÆÁ÷±îÁö ÀÌ·¯ÇÑ ±Þ¹ÚÇÏÁöÇãÇ÷Áõ »óÅ¿¡¼­ µ¿¸ÆÀç°³Åë¼úÀÇ Ç¥ÁØÄ¡·á¹ýÀº µ¿¸Æ¿ìȸ¼úÀÌ´Ù. ±×·¯³ª ±Ù·¡ ±Þ¼ÓÈ÷ ¹ß´ÞÇÏ°í ÀÖ´Â Ç÷°ü³»Ä¡·á¹ýÀº µ¿¸Æ¿ìȸ¼úÀÌ ºÒ°¡´ÉÇÑ È¯ÀÚ³ª ÇغÎÇÐÀûÀ¸·Î Ä¡·á°¡ ¿ëÀÌÇÑ È¯ÀÚµéÀº ´ë»óÀ¸·Î ±× ÀûÀÀÁõÀ» È®´ëÇÏ°í ÀÖ´Ù. ¿©±â¼­´Â ´ç´¢º´ ȯÀÚ¿¡¼­ ½ÃÇàµÇ´Â µ¿¸ÆÀç°³Åë¼ú¿¡ ´ëÇÏ¿© °³·«ÀûÀ¸·Î »ìÆ캸°íÀÚ ÇÑ´Ù.



º» ·Ð



±âº» ¿øÄ¢ ¹× ȯÀÚ ¼±ÅÃ



´ç´¢º´¼º Á·ºÎ ±Ë¾çÀ» ÁÖ¼Ò·Î ³»¿øÇϴ ȯÀڵ鿡°Ô °¡Àå ¸ÕÀú ½ÃÇàÇØ¾ß ÇÒ Ã³Ä¡´Â ±¹¼Ò °¨¿°À» ¿Ü°úÀû ¹× ³»°úÀûÀ¸·Î Á¶ÀýÇÏ´Â °ÍÀÌ´Ù. ÇÊ¿äÇÏ¸é ¹è¾×¼ú, º¯¿¬ÀýÁ¦¼ú, Àý´Ü¼ú µîÀ» Á¶±â¿¡ ½ÃÇàÇÏ¿©¾ß ÇÑ´Ù. ÀÌ·¯ÇÑ È¯Àڵ鿡¼­ ÇÏÁöÀÇ µ¿¸ÆÇ÷·ù »óŸ¦ ÆľÇÇÏ´Â °ÍÀº ÀÌÈÄÀÇ Ä¡·á ¹æħÀ» °áÁ¤Çϴµ¥ ÇʼöÀûÀÌ´Ù. ÈçÈ÷ »ç¿ëµÇ´Â ¹ß¸ñµ¿¸Æ¾ÐÁö¼ö(ankle-brachial pressure index, ABI)´Â ´ç´¢º´ÀÌ ¿À·¡µÈ ȯÀÚÀÇ °æ¿ì¿¡´Â µ¿¸ÆÀÇ ¼®È¸È­·Î ÀÎÇÏ¿© ºñÁ¤»óÀûÀ¸·Î ³ô°Ô ÃøÁ¤µÉ ¼ö ÀÖÀ¸¹Ç·Î ¹Ýµå½Ã Ç÷·ùÆÄÇüÀ» ÇÔ²² °í·ÁÇÏ¿©¾ß Çϸç, À̶§ Á·ÁöºÎÀÇ Ç÷·ù »óŸ¦ ÇÔ²² °Ë»çÇÏ´Â °ÍÀÌ µµ¿òÀÌ µÈ´Ù. ÀÌ·± ȯÀڵ鿡¼­ Á·Áöµ¿¸Æ¾ÐÁö¼ö(toe-brachial pressure index, TBI)´Â ABIº¸´Ù ´õ Á¤È®È÷ ÇÏÁöÀÇ Ç÷·ù »óŸ¦ ³ªÅ¸³¾ ¼ö ÀÖÀ¸³ª(8), ±Ë¾çÀÌ ÀÌȯµÈ ºÎÀ§°¡ Á·Áö Àü¹Ý¿¡ °ÉÃÄ ÀÖ´Â °æ¿ì¿¡´Â °Ë»ç°¡ ºÒ°¡´ÉÇϸç Çö½ÇÀûÀ¸·Î ±¹³»¿¡¼­´Â ¾ÆÁ÷ º¸ÆíÈ­µÇ¾î ÀÖÁö ¸øÇÑ °Í °°´Ù. ÀÏ´Ü ÇÏÁöµ¿¸ÆÆó»öÁõÀÌ ÀÇ½ÉµÇ¸é µ¿¸ÆÀç°³Åë¼úÀ» °èȹÇϱâ À§ÇÑ ¿µ»óÇÐÀû °Ë»ç°¡ ¹Ýµå½Ã ÇÊ¿äÇϸç, ȯÀÚÀÇ ½ÅÀå±â´É¿¡ ¾Æ¹«·± ¹®Á¦°¡ ¾ø´Ù¸é ±Ù·¡¿¡´Â CT-Ç÷°üÁ¶¿µ¼úÀÌ º¸ÆíÀûÀ¸·Î ÀÌ¿ëµÇ°í ÀÖ´Ù. Åõ¼®À» ½ÃÇàÇÏ°í ÀÖÁö ¾Ê´Â °æ°è¼º ¸¸¼º½ÅºÎÀüÁõ ȯÀڵ鿡¼­´Â Á¶¿µÁ¦°¡ ÇÊ¿äÇÑ CT-Ç÷°üÁ¶¿µ¼úÀÇ »ç¿ë¿¡ ÁÖÀÇÇÏ¿©¾ß ÇÑ´Ù. ÀÌ·± ȯÀڵ鿡¼­´Â Á¶¿µÁ¦ÀÇ »ç¿ëÀ» ÃÖ¼ÒÈ­ÇÒ ¼ö ÀÖ´Â °íÀüÀûÀÎ Ç÷°üÁ¶¿µ¼úÀ» »ç¿ëÇÒ ¼öµµ ÀÖÁö¸¸ ±Ù·¡ ±¤¹üÀ§ÇÏ°Ô »ç¿ëµÇ°í ÀÖ´Â µàÇ÷º½ºÃÊÀ½Æĸ¦ ÀÌ¿ëÇÏ¸é °³·«ÀûÀÎ Ä¡·áÀü·«À» ¼ö¸³Çϴµ¥ µµ¿òÀÌ µÈ´Ù.

´ç´¢º´¼º Á·ºÎ ±Ë¾ç ȯÀÚÀÇ Ä¡·á ¸ñÀûÀº ÅëÁõ ¿ÏÈ­¿Í »óó Ä¡À¯¸¦ ÅëÇÏ¿© ±â´ÉÀûÀÎ ÇÏÁö¸¦ À¯ÁöÇÏ°í º¸ÇàÀÌ °¡´ÉÇÏ°Ô ÇÏ´Â °ÍÀÌ´Ù. À̸¦ À§Çؼ­´Â ÀÌ·¯ÇÑ È¯Áöµé¿¡°Ô µ¿¸ÆÀç°³Åë¼úÀ» ½ÃÇàÇϱâ Àü¿¡ ȯÀÚÀÇ È°µ¿ ´É·ÂÀ̳ª ¿©¸íÀ» ÃßÁ¤ÇÏ´Â °ÍÀÌ Ä¡·áÀÇ ÇüŸ¦ °áÁ¤Çϴµ¥ ¸Å¿ì Áß¿äÇÏ´Ù. ±Þ¹ÚÇÏÁöÇãÇ÷Áõ ȯÀÚ°¡ 1³â ³» »ç¸ÁÇÒ È®·üÀº 15%-20%, ÇÏÁöÀý´Ü·üÀº 40% Á¤µµ·Î º¸°íµÇ°í ÀÖÀ¸¸ç(9), ´ç´¢º´À» °¡Áø ȯÀڵ鿡¼­´Â »ç¸Á·ü°ú ÇÏÁöÀý´Ü·üÀÌ À̺¸´Ù ´õ ³ôÀº °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù(10). µû¶ó¼­ ¼ö¼ú ÈÄ 30ÀÏ »ç¸Á·üÀÌ µ¿¸Æ¿ìȸ¼ú(2%-6%)°ú Ç÷°ü³»Ä¡·á(2%-8%) ¸ðµÎ ºñ½ÁÇÑ °ÍÀ¸·Î º¸°íµÇ°í(11-17) ÀÖ´Â °ÍÀ» °¨¾ÈÇÏ´õ¶óµµ ȯÀÚÀÇ ½ÉÀå »óųª Æó±â´É Á¤µµ, È°µ¿ ´É·Â ¹× °¢ ¼¾ÅÍ°¡ º¸À¯ÇÏ°í ÀÖ´Â Ä¡·á ¼ºÀû µîÀ» °¨¾ÈÇÏ¿© ȯÀÚ¿¡ ¸Â´Â ¸ÂÃãÇü Ä¡·á¸¦ ½ÃÇàÇÏ¿©¾ß ÇÑ´Ù. ȯÀÚ °³°³ÀÎÀÇ ¼ö¼ú À§Çèµµ´Â PREVENT III(17,18), Finnvasc(19,20), BASIL(21) µîÀÇ ¿¬±¸¿¡¼­ »ç¿ëµÈ Ç׸ñµéÀ» Âü°í·Î ÇÏ¿© °¢ ¼¾ÅÍÀÇ ¼ºÀûÀ» ºñ±³ ºÐ¼®ÇÏ¸é ¾î´À Á¤µµ ÃßÁ¤ÇÒ ¼ö´Â ÀÖ°ÚÀ¸³ª, ȯÀÚÀÇ »óÅ ¹× Àý´ÜÀ» ±ØÈ÷ ½È¾îÇÏ´Â ±¹³» ¹®È­ µîÀ» °í·ÁÇϸé ÀÌ·¯ÇÑ °´°üÀû ÁöÇ¥°¡ ½ÇÁ¦ÀûÀ¸·Î Àû¿ëµÇ±â¿¡´Â ÇÑ°èÁ¡ÀÌ ÀÖÀ» ¼ö ÀÖ´Ù. ÀúÀÚÀÇ °æÇè¿¡ µû¸£¸é Åõ¼®¿¡ ÀÇÁ¸ÇÏ°í ÀÖ´Â ´ç´¢º´¼º ¸¸¼º½ÅºÎÀüÁõ ȯÀÚ¿¡¼­ Á·ºÎ ±Ë¾çÀÇ ¹üÀ§°¡ ³Ð°í, È°µ¿¼º °¨¿°ÀÎ °æ¿ì¿¡´Â ÇÏÁö±¸Á¦·üÀÌ ³·¾Æ¼­ ÀÌ·¯ÇÑ È¯Àڵ鿡¼­´Â ÇÏÁöÀý´Ü¼úÀ» ½ÃÇàÇÒ °ÍÀ» ±Ç°íÇÑ´Ù.



Ç÷°ü³»Ä¡·á



±Þ¼ÓÈ÷ ¹ßÀüÇÏ°í ÀÖ´Â ±â¼ú·ÂÀ» ¹ÙÅÁÀ¸·Î Ä«Å×Å͸¦ ºñ·ÔÇÑ ¿©·¯ »õ·Î¿î ±â±¸µéÀÇ °³¹ß, ±×¸®°í À̸¦ ÀÌ¿ëÇÑ ¼ú±âÀÇ ¹ßÀü µîÀ¸·Î ±Ù·¡´Â °¡È÷ Ç÷°ü³»Ä¡·áÀÇ ½Ã´ë¶ó°í ÇÒ ¼ö ÀÖ´Ù. Ç÷°ü³»Ä¡·áÀÇ °¡Àå Å« ÀåÁ¡Àº Ä¡·á ¹æ¹ýÀÇ °£ÆíÇÔ, ªÀº ȸº¹±â°£ ¹× ÀÔ¿øÀϼö, ºñ±³Àû ÀûÀº °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Â ¼ö¼ú ÈÄ ÇÕº´Áõ ¹ß»ý µîÀÌ´Ù. ±×·¯³ª À̸¥ ½Ã±â¿¡ ¹ß»ýÇÏ´Â ÀçÇùÂøÀ¸·Î ÀÎÇÑ Áõ»óÀÇ Àç¹ß, ÃæºÐÇÑ Ç÷·ù¸¦ °ø±ÞÇÏÁö ¸øÇÔ¿¡ µû¸¥ »óóÀÇ Ä¡À¯ Áö¿¬ ¹× Àç¹ß, Àç½Ã¼ú¿¡ µû¸£´Â »çȸ°æÁ¦Àû ºÎ´ã ¹× ÇÕº´ÁõÀÇ Áõ°¡ µîÀº Ç÷°ü³»Ä¡·á°¡ ¾È°í ÀÖ´Â °¡Àå Å« °áÁ¡À̱⵵ ÇÏ´Ù. ±Ù·¡ ºñ±³Àû ¿ì¼öÇÑ ¼¾Å͵鿡¼­ º¸°íµÇ°Å³ª ¸ÞŸºÐ¼®À» ÅëÇØ ¾Ë·ÁÁø Ç÷°ü³»Ä¡·áÀÇ ¼ºÀûÀº 80%¸¦ »óȸÇÏ´Â ´Ü±â ¹× Áß±â ÇÏÁö±¸Á¦·üÀ» º¸°íÇÏ°í ÀÖ´Ù(11,12,14,22,23). ºñ±³Àû ÃʱâÀÇ ÇÏÁö±¸Á¦·ü ¼ºÀûÀº ¸¸Á·½º·´Áö¸¸ ¾ÆÁ÷ Àå±âÀûÀÎ ¼ºÀûÀº µ¿¸Æ¿ìȸ¼ú¿¡ ºñÇÏ¿© ¸¹ÀÌ ¶³¾îÁö´Â °Íµµ »ç½ÇÀÌ´Ù. ƯÈ÷ TASC D º´º¯, Á¶Á÷ ¼Õ½ÇÀÌ ÀÖ´Â °æ¿ì, ±×¸®°í ´ç´¢º´ ȯÀÚ µî¿¡¼­´Â Ç÷°ü³»Ä¡·áÀÇ ¼ºÀûÀÌ ´õ¿í ³ª»Û °ÍÀ¸·Î º¸°íµÇ°í ÀÖ´Ù(12,22). ÀúÀÚÀÇ °æ¿ì¿¡µµ ´ç´¢º´¼º ¸¸¼º½ÅºÎÀüÁõ ȯÀڵ鿡¼­ ÇÏÁö±¸Á¦¸¦ À§ÇÏ¿© ½ÃÇàÇÑ Ç÷°ü¼ºÇü¼úÀº Á¶±â¿¡ ÀçÇùÂøµÇ¾î Áõ»ó ¹× ±Ë¾çÀÌ Àç¹ßÇÏ´Â °ÍÀ» °æÇèÇÏ¿´À¸¸ç, ÀÌ·¯ÇÑ È¯Àڵ鿡¼­´Â °¡´ÉÇÏ¸é µ¿¸Æ¿ìȸ¼úÀ» ½ÃÇàÇÏ´Â °ÍÀÌ Àå±âÀûÀÎ Ç÷·ù°³¼± È¿°ú¸¦ È®º¸Çϴµ¥ ¿ì¼öÇÑ °ÍÀ¸·Î »ý°¢µÇ¾ú´Ù. ±×·¯³ª ÇöÀç Ç÷°ü³»Ä¡·áÀÇ ÁÖ°üÀû ¿ì¼ö¼ºÀÌ ³Ê¹« ±¤¹üÀ§ÇÏ°Ô È¯Àڵ鿡°Ô È«º¸µÇ¾î À־ Ä¡·á¹æħ°ú ´Ù¸£°Ô Ç÷°ü³»Ä¡·á¸¦ ¼±ÅÃÇÏ´Â °æ¿ìµµ Çã´ÙÇÏ´Ù. ÇöÀç Ç÷°ü³»Ä¡·áÀÇ Àå±â°³Á¸·üÀ» È®º¸Çϱâ À§ÇÑ ³ë·ÂÀ¸·Î ¾à¹°À» ÄÚÆÃÇÑ Ç³¼±(drug-coated balloon, DCB)À» ÀÌ¿ëÇϰųª ¾à¹°À» ¹æÃâÇÏ´Â ½ºÅÙÆ®(drug-eluting stent, DES)¸¦ ÀÌ¿ëÇÑ Ç÷°ü³»Ä¡·á°¡ ½ÃÇàµÇ°í ÀÖÀ¸³ª ¾ÆÁ÷ ±× ¼ºÀû¿¡ ´ëÇؼ­´Â º¸´Ù ¸¹Àº ¿¬±¸°¡ ÇÊ¿äÇÒ °ÍÀ¸·Î º¸ÀδÙ.



µ¿¸Æ¿ìȸ¼ú



ÀÚ°¡Ç÷°ü À̽ÄÆíÀ» ÀÌ¿ëÇÑ µ¿¸Æ¿ìȸ¼úÀº ¿©ÀüÈ÷ ±Þ¹ÚÇÏÁöÇãÇ÷ÁõÀÌ Àִ ȯÀڵ鿡°Ô ½ÃÇàµÉ ¼ö ÀÖ´Â °¡Àå ÁÁÀº Ä¡·á¹ýÀÌ´Ù. ±×·¯³ª ±Ù·¡ ±¤¹üÀ§ÇÏ°Ô ½ÃÇàµÇ°í ÀÖ´Â Ç÷°ü³»Ä¡·á¿¡ ºñÇÏ¿© ³ôÀº ¼ö¼ú ÈÄ ÇÕº´Áõ ¹ß»ý·üÀÌ µ¿¸Æ¿ìȸ¼úÀÇ °¡Àå Å« ´ÜÁ¡ÀÌ´Ù. °æ°ñµ¿¸ÆÀ̳ª Á·ºÎµ¿¸Æ°ú °°Àº ÀÛÀº µ¿¸Æ¿¡ ´ëÇÏ¿© ½ÃÇàÇÏ´Â µ¿¸Æ¿ìȸ¼úÀÌ¶óµµ 5³â Àå±â°³Á¸·üÀº 50%-70%, ÇÏÁö±¸Á¦·üÀº 80%¸¦ »óȸÇÏ¿© Ç÷°ü³»Ä¡·á¿¡ ºñÇÏ¿© º¸´Ù ¿ì¼öÇÑ Àå±â ¼ºÀûÀ» º¸°íÇÏ°í ÀÖ´Ù(9). ÀÌ·¯ÇÑ °á°ú´Â ¾çÁúÀÇ ´ëº¹ÀçÁ¤¸ÆÀ» À̽ÄÆíÀ¸·Î »ç¿ëÇÏ´Â °æ¿ì ´õ¿í Çâ»óµÇ¸ç, ¿øÀ§ºÎ ¹®ÇÕºÎÀÇ À§Ä¡³ª ´ç´¢º´ÀÇ À¯¹«¿¡µµ ¿µÇâÀ» ¹ÞÁö ¾Ê´Â °ÍÀ¸·Î º¸°íµÇ°í ÀÖ´Ù(17,24,25). ¶ÇÇÑ µ¿¸Æ¿ìȸ¼úÀº Ç÷°ü³»Ä¡·áº¸´Ù ÃæºÐÇÑ Ç÷·ù¸¦ ±Ë¾ç ºÎÀ§¿¡ °ø±ÞÇÒ ¼ö À־ »óó Ä¡À¯ ±â°£À» ´ÜÃà½ÃÅ°´Â °ÍÀ¸·Î º¸°íµÇ°í ÀÖ´Ù(26). ´Ù¸¸ ÀåµýÁö ÇϺÎÀÇ ¿øÀ§ºÎ µ¿¸ÆÀ̳ª Á·ºÎµ¿¸Æ¿¡ µ¿¸Æ¿ìȸ¼úÀ» ½ÃÇàÇϱâ À§Çؼ­´Â ÃæºÐÇÑ °æÇè°ú ¼÷·ÃµÈ ¼ú±â°¡ ÇÊ¿äÇϸç, ¾çÁúÀÇ ´ëº¹ÀçÁ¤¸Æ À̽ÄÆíÀÇ È®º¸°¡ ÇʼöÀûÀÌ´Ù(27,28). ¿©·¯ °¡Áö ¹®Á¦Á¡Àº ÀÖÁö¸¸ ±×·¡µµ ÇöÀç±îÁö µ¿¸Æ¿ìȸ¼ú°ú Ç÷°ü³»Ä¡·á ¼ºÀûÀ» ºñ±³ ºÐ¼®ÇÑ À¯ÀÏÇÑ ´ë±Ô¸ð ¿¬±¸ÀÎ BASIL ¿¬±¸(21)¿¡¼­´Â ¿ì¼öÇÑ ÀÚ°¡Á¤¸Æ À̽ÄÆíÀÌ È®º¸µÈ »óȲ¿¡¼­´Â µ¿¸Æ¿ìȸ¼úÀ» ¿ì¼±ÀûÀ¸·Î ½ÃÇàÇÒ °ÍÀ» ±Ç°íÇÏ°í ÀÖ´Ù. ÀÚ°¡Á¤¸Æ À̽ÄÆíÀÌ ¾ø´Â °æ¿ì¿¡ »ç¿ëµÇ´Â ÀÎÁ¶Ç÷°ü À̽ÄÆíÀ» »ç¿ëÇÑ °æ¿ì¿¡´Â ±× ¼ºÀûÀÌ ÇöÀúÈ÷ °¨¼ÒµÈ´Ù. ÀÌ·¯ÇÑ ÀÎÁ¶Ç÷°ü À̽ÄÆíÀÇ ´ÜÁ¡À» º¸¿ÏÇϱâ À§ÇÑ ¿©·¯ °¡Áö ¼ú±âµéÀÌ »ç¿ëµÇ°í ÀÖ°í, ÇìÆĸ°À» ºÎÂøÇÑ ÀÎÁ¶Ç÷°ü À̽ÄÆíÀÌ °³¹ßµÇ±âµµ ÇßÀ¸³ª, ¾ÆÁ÷±îÁö´Â º¸´Ù ¸¹Àº ¿¬±¸°¡ ÇÊ¿äÇÒ °ÍÀ¸·Î º¸ÀδÙ.



°á ·Ð



´ç´¢º´¼º Á·ºÎ ±Ë¾çÀ» °¡Áø ÇÏÁöÇãÇ÷Áõ ȯÀڵ鿡¼­ °¡Àå ÁÁÀº Àå±â ¼ºÀûÀ» º¸ÀÌ´Â °ÍÀº ÀÚ°¡Ç÷°ü À̽ÄÆíÀ» ÀÌ¿ëÇÑ µ¿¸Æ¿ìȸ¼úÀÌ´Ù. ±×·¯³ª ȯÀÚÀÇ »óÅ¿¡ µû¶ó µ¿¸Æ¿ìȸ¼úÀº Ç÷°ü³»Ä¡·á¿¡ ºñÇÏ¿© ³ôÀº ¼ö¼ú ÈÄ ÇÕº´ÁõÀ» º¸ÀÌ°í ÀÖÀ¸¸ç, ÀÌ·Î ÀÎÇØ ±Ù·¡¿¡´Â Ç÷°ü³»Ä¡·á°¡ ±¤¹üÀ§ÇÏ°Ô »ç¿ëµÇ°í ÀÖ´Ù. Ç÷°ü³»Ä¡·á´Â Ä¡·áÀÇ °£Æí¼º°ú ºü¸¥ ȸº¹ ±â°£ µîÀÇ ÀåÁ¡ÀÌ ÀÖÀ¸³ª, ÀçÇùÂøÀÇ ºóµµ°¡ ³ô´Ù´Â °ÍÀÌ Ä¡¸íÀûÀÎ ´ÜÁ¡ÀÌ´Ù. µû¶ó¼­ ȯÀÚÀÇ ¿©¸í ¹× µ¿¹ÝÁúȯ »óÅÂ, ÀÚ°¡Á¤¸Æ À̽ÄÆíÀÇ À¯¹«, µ¿¸ÆÆó»ö ºÎÀ§ÀÇ ÇغÎÇÐÀû À§Ä¡ µîÀ» °í·ÁÇÏ¿© ȯÀÚ °³°³Àο¡ ¸Â´Â ¸ÂÃãÇü Ä¡·á¸¦ ½ÃÇàÇÏ¿©¾ß ´ç´¢º´¼º Á·ºÎ ±Ë¾çÀ» °¡Áø ÇÏÁöÇãÇ÷Áõ ȯÀڵ鿡°Ô °¡Àå ³ôÀº »îÀÇ ÁúÀ» Á¦°øÇÒ ¼ö ÀÖÀ» °ÍÀÌ´Ù.



Âü°í¹®Çå



1. Kim DJ: The epidemiology of diabetes in Korea. Diabetes Metab J 35:303-308, 2011

2. Task Force Team for Basic Statistical Study of Korean Diabetes Mellitus: Report of Task Force Team for Basic Statistical Study of Korean Diabetes Mellitus: diabetes in Korea 2007. 1st ed. Seoul: Goldfishery; 2007.

3. Lipsky BA, Peters EJ, Berendt AR, et al: Specific guidelines for the treatment of diabetic foot infections 2011. Diabetes Metab Res Rev 28:234-235, 2012 (suppl 1)

4. Bakker K, Apelqvist J, Schaper NC: Practical guidelines on the management and prevention of the diabetic foot 2011. Diabetes Metab Res Rev 28:225-231, 2012 (suppl 1)

5. Game FL, Hinchliffe RJ, Apelqvist J, et al: Specific guidelines on wound and wound-bed management 2011. Diabetes Metab Res Rev 28:232-233, 2012 (suppl 1)

6. º¸°Çº¹ÁöºÎÁöÁ¤ 2Çü ´ç´¢º´ Àӻ󿬱¸¼¾ÅÍ: ´ç´¢º´ÀÇ ¸»Ãʵ¿¸ÆÁúȯ Áø·áÁöħ.

7. Faglia E, Clerici G, Clerissi J, et al: Long-term prognosis of diabetic patients with critical limb ischemia: a population-based cohort study. Diabetes Care 32:822-827, 2009

8. Cao P, Eckstein HH, de Rango P, et al: Chapter II: diagnostic methods. Eur J Vasc Endovasc 42:S13-S32, 2011 (suppl2)

9. Norgren L, Hiatt WR, Dormandy JA, et al: Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 45:S5-S67, 2007 (suppl)

10. Malmstedt J, Leander K, Wahlberg E, et al: Outcome after leg bypass surgery for critical limb ischemia is poor in patients with diabetes: a population-based cohort study. Diabetes Care 31:887-892, 2008

11. Romiti M, Albers M, Brochado-Neto FC, et al: Meta-analysis of infrapopliteal angioplasty for chronic critical limb ischemia. J Vasc Surg 47:975-981, 2008

12. Giles KA, Pomposelli FB, Hamdan AD, et al: Infrapopliteal angioplasty for critical limb ischemia: relation of transatlantic intersociety consensus class to outcome in 176 limbs. J Vasc Surg 48:128-136, 2008

13. Bradbury AW, Adam DJ, Bell J, et al: Bypass versus angioplasty in severe ischaemia of the leg (basil) trial: an intention-to-treat analysis of amputation-free and overall survival in patients randomized to a bypass surgery-first or a balloon angioplasty-first revascularization strategy. J Vasc Surg 51:5S-17S, 2010 (suppl)

14. Conrad MF, Crawford RS, Hackney LA, et al: Endovascular management of patients with critical limb ischemia. J Vasc Surg 53:1020-1025, 2011

15. Vogel TR, Dombrovskiy VY, Carson JL, et al: In-hospital and 30-day outcomes after tibioperoneal interventions in the US Medicare population with critical limb ischemia. J Vasc Surg 54:109-115, 2011

16. Conte MS, Belkin M, Upchurch GR, et al: Impact of increasing comorbidity on infrainguinal reconstruction: a 20-year perspective. Ann Surg 233:445-452, 2001

17. Conte MS, Bandyk DF, Clowes AW, et al: Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg 43:742-751; discussion 751, 2006

18. Schanzer A, Mega J, Meadows J, et al: Risk stratification in critical limb ischemia: derivation and validation of a model to predict amputation free survival using multicenter surgical outcomes data. J Vasc Surg 48:1464-1471, 2008

19. Biancari F, Salenius JP, Heikkinen M, et al: Risk-scoring method for prediction of 30-day postoperative outcome after infrainguinal surgical revascularization for critical lower-limb ischemia: a finnvasc registry study. World J Surg 31:217-225; discussion 226-217, 2007

20. Arvela E, Soderstrom M, Korhonen M, et al: Finnvasc score and modified PREVENT III score predict long-term outcome after infrainguinal surgical and endovascular revascularization for critical limb ischemia. J Vasc Surg 52:1218-1225, 2010

21. Bradbury AW, Adam DJ, Bell J, et al: Bypass Versus Angioplasty in Severe Ischaemia of The Leg (BASIL) Trial: a survival prediction model to facilitate clinical decision making. J Vasc Surg 51:52S-68S, 2010 (suppl)

22. Derubertis BG, Pierce M, Ryer EJ, et al: Reduced primary patency rate in diabetic patients after percutaneous intervention results from more frequent presentation with limb-threatening ischemia. J Vasc Surg 47:101-108, 2008

23. Laird JR, Zeller T, Gray BH, et al: Limb salvage following laser-assisted angioplasty for critical limb ischemia: results of the Laci multicenter trial. J Endovasc Ther 13:1-11, 2006

24. Singh N, Sidawy AN, Dezee KJ, et al: Factors associated with early failure of infrainguinal lower extremity arterial bypass. J Vasc Surg 47:556-561, 2008

25. Akbari CM, Pomposelli FB Jr, Gibbons GW, et al: Lower extremity revascularization in diabetes: Late observations. Arch Surg 135:452-456, 2000

26. Neville RF, Sidawy AN: Surgical bypass: when is it best and do angiosomes play a role? Semin Vasc Surg 25:102-107, 2012

27. Schanzer A, Hevelone N, Owens CD, et al: Technical factors affecting autogenous vein graft failure: observations from a large multicenter trial. J Vasc Surg 46:1180-1190; discussion 1190, 2007

28. Conte MS: Technical factors in lower-extremity vein bypass surgery: how can we improve outcomes? Semin Vasc Surg 22:227-233, 2009